Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.
EP: 1.Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)
EP: 2.Ongoing Research on Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer
Now Viewing
EP: 3.Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
EP: 4.Expert Insights on Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
EP: 5.Emerging Data in Metastatic Urothelial Carcinoma
EP: 6.Clinical Insights on Recent Data in Metastatic Urothelial Carcinoma
EP: 7.Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma
EP: 8.Later-Line Therapies for Metastatic Urothelial Carcinoma
EP: 9.Treatment Sequencing Practices in Metastatic Urothelial Carcinoma
EP: 10.Exciting New Approaches in Metastatic Urothelial Carcinoma
EP: 11.Key Takeaways on Updates in Bladder Cancer
Related Videos
Related Content
